January 8, 2019
Regen Biopharma’s lead NR2F6 agonist combined with Cannabidiol (CBD) could treat Inflammatory Bowel Disease
Regen BioPharma’s researches have combined its lead NR2F6 small molecule agonist with Cannabidiol (CBD) to provide a dynamic therapy for treating inflammatory bowel disease (IBD), and it could work.